Glen Pierce

List of Publications by Year
in descending order

57 papers	7,705 citations	159525 30 h-index	155592 55 g-index
57 all docs	57 docs citations	57 times ranked	4691 citing authors

#	Article	IF	Citations
1	Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. New England Journal of Medicine, 2022, 386, 1013-1025.	13.9	157
2	Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nature Medicine, 2022, 28, 789-797.	15.2	48
3	Supporting patients with haemophilia in a world of crises: New role for the WFH and its partners. Haemophilia, 2022, 28, 521-522.	1.0	0
4	Results of genetic analysis of 11â€‰341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal of Thrombosis and Haemostasis, 2022, 20, 2022-2034.	1.9	10
5	Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns. Haemophilia, 2021, 27, 103-113.	1.0	28
6	Management of COVIDâ€19â€associated coagulopathy in persons with haemophilia. Haemophilia, 2021, 27, 41-48.	1.0	14
7	Reimbursing the value of gene therapy care in an era of uncertainty. Haemophilia, 2021, 27, 12-18.	1.0	7
8	Impact of humanitarian aid linked prophylaxis in CÃ´te d'Ivoire (Ivory Coast). Haemophilia, 2021, 27, 9-11.	1.0	3
9	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	1.0	9
10	Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia, 2021, 27, 947-956.	1.0	62
11	Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327.	3.7	12
12	Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. New England Journal of Medicine, 2020, 382, 29-40.	13.9	316
13	Gene Therapy for Hemophilia: Are Expectations Matching Reality?. Molecular Therapy, 2020, 28, 2097-2098.	3.7	8
14	Gene therapy for hemophilia: anticipating the unexpected. Blood Advances, 2020, 4, 3788-3788.	2.5	8
15	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
16	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	1.9	24
17	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	1.0	24
18	Activity of transgene-produced B-domainâ€“deleted factor VIII in human plasma following AAV5 gene therapy. Blood, 2020, 136, 2524-2534.	0.6	48

#	Article	IF	Citations
19	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	1.0	28
20	The World Federation of Hemophilia Annual Global Survey 1999â€2018. Haemophilia, 2020, 26, 591-600.	1.0	50
21	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	1.0	15
22	The COVIDâ€19 pandemic: New global challenges for the haemophilia community. Haemophilia, 2020, 26, 371-372.	1.0	21
23	Liver Gene Therapy: Reliable and Durable?. Molecular Therapy, 2019, 27, 1863-1864.	3.7	20
24	The 1st <scp>WFH</scp> Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia, 2019, 25, 189-194.	1.0	31
25	Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Advances, 2019, 3, 1-4.	2.5	17
26	World bleeding disorders registry: The pilot study. Haemophilia, 2018, 24, e113-e116.	1.0	13
27	Firstâ€year results of an expanded humanitarian aid programme for haemophilia in resourceâ€constrained countries. Haemophilia, 2018, 24, 229-235.	1.0	32
28	Core outcome set for gene therapy in haemophilia: Results of the core<scp>HEM</scp> multistakeholder project. Haemophilia, 2018, 24, e167-e172.	1.0	74
29	Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia, 2018, 24, 60-67.	1.0	35
30	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	1.0	18
31	A Cornucopia of Therapies under Study for Hemophilia. Molecular Therapy, 2017, 25, 2429-2430.	3.7	4
32	AAV5â€“Factor VIII Gene Transfer in Severe Hemophilia A. New England Journal of Medicine, 2017, 377, 2519-2530.	13.9	529
33	Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Advances, 2017, 1, 824-834.	2.5	83
34	Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study. Japanese Journal of Thrombosis and Hemostasis, 2016, 27, 665-677.	0.1	0
35	Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis, 2016, 116, 1-8.	1.8	52
36	Longâ€term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia, 2016, 22, 72-80.	1.0	98

#	Article	IF	Citations
37	Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice. PLoS ONE, 2016, 11, e0148255.	1.1	2
38	Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals. Thrombosis Research, 2015, 136, 371-378.	0.8	6
39	Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals. Thrombosis Research, 2015, 136, 1266-1272.	0.8	3
40	Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Critical Reviews in Biotechnology, 2015, 35, 235-254.	5.1	201
41	Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia, 2014, 20, 294-300.	1.0	84
42	Recombinant factorÂVIII Fc fusion protein: extendedâ€interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of Thrombosis and Haemostasis, 2014, 12, 1788-1800.	1.9	56
43	Validation of the manufacturing process used to produce longâ€acting recombinant factor <scp>IX</scp> Fc fusion protein. Haemophilia, 2014, 20, e327-35.	1.0	30
44	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood, 2014, 123, 317-325.	0.6	403
45	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323.	13.9	307
46	Biochemical and functional characterization of a recombinant monomeric factorÂVIIIâ€“Fc fusion protein. Journal of Thrombosis and Haemostasis, 2013, 11, 132-141.	1.9	116
47	Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 2012, 119, 666-672.	0.6	167
48	Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 2012, 119, 3031-3037.	0.6	215
49	Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 2012, 119, 3024-3030.	0.6	139
50	CD8+ T-cell responses to adeno-associated virus capsid in humans. Nature Medicine, 2007, 13, 419-422.	15.2	629
51	Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. Molecular Therapy, 2006, 14, 452-455.	3.7	196
52	Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 2006, 108, 3321-3328.	0.6	295
53	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	15.2	1,865
54	Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties. Journal of Virology, 2005, 79, 15238-15245.	1.5	65

#	Article	IF	Citations
55	Gene therapy: reality or myth for the global bleeding disorders community?. Haemophilia, 2002, 8, 261-267.	1.0	32
56	The Use of Purified Clotting Factor Concentrates in Hemophilia. JAMA - Journal of the American Medical Association, 1989, 261, 3434.	3.8	41
57	The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. JAMA - Journal of the American Medical Association, 1989, 261, 3434-3438.	3.8	40